Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: Is it time to change treatment?

Pediatric Blood and Cancer

Volumn 54, Issue 2, 2010, Pages 193-198

  Ruggiero, Antonio ^a   Rizzo, Daniela ^a   Mastrangelo, Stefano ^a   Battaglia, Domenica ^a   Attinà, Giorgio ^a   Riccardi, Riccardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antiepileptic drugs; Brain tumors; Chemotherapy; Interaction; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBAMAZEPINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOCETAXEL; ETIRACETAM; ETOPOSIDE; FELBAMATE; GLYCOPROTEIN P INHIBITOR; IRINOTECAN; LAMOTRIGINE; METHOTREXATE; OXCARBAZEPINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROCARBAZINE; TAMOXIFEN; TENIPOSIDE; TOPIRAMATE; TOPOTECAN; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; HEADACHE; HUMAN; MULTIDRUG RESISTANCE; NONLYMPHATIC LEUKEMIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; PIRACETAM; SEIZURES;

EID: 74849115324     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22276     Document Type: Review

References (60)

1. Ibrahim K, Appleton R. Seizures as the presenting symptom of brain tumours in children. Seizure 2004;13:108-112.
2. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002;14:299-307.
3. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000;54:1886-1893.
4. Vecht CJ, Wagner GL, Wilms EB. Treating seizures in patients with brain tumors: Drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003;30:49-52.
5. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404-409.
6. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259.
7. Chang SM, Kuhn JG, Rizzo J, et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report. J Clin Oncol 1998;16:2188-2194.
8. Villikka K, Kivisto KT, Maenpaa H, et al. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999;66:589-593.
9. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-1353.
10. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285-290.
11. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006;8: 67-78.
12. Grenader T, Gipps M, Shavit L, et al. Significant drug interaction: Phenytoin toxicity due to erlotinib. Lung Cancer 2007;57:404-406.
13. Van der Bent MJ. The role of chemotherapy in brain metastasis. Eur J Cancer 2003;39:2114-2120.
14. Chalk JB, Ridgeway K, Brophy T, et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984;47:1087-1090.
15. Gambertoglio JG, Holford NH, Kapusnik JE, et al. Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int 1984;25:119-123.
16. Brooks PM, Buchanan WW, Grove M, et al. Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. Ann Rheum Dis 1976;35:339-343.
17. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 2006;78:99-102.
18. Wagner GL, Wilms EB, Van Donselaar CA, et al. Levetiracetam: Preliminary experience in patients with primary brain tumours. Seizure 2003;12:585-586.
19. Perry JRSC. Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 1996;23:128-131.
20. Koukkari MW, Guarino EJ. Retrospective study of the use of levetiracetam in childhood seizure disorders. J Child Neuro1 2004; 19:944-947.
21. Bello-Espinosa LE, Roberts SL. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes: Three cases. Seizure 2003;12:157-159.
22. Kossoff EH, Boatman D, Freeman JM. Landau-Kleffner syndrome responsive to levetiracetam. Epilepsy Behav 2003;4:571-575.
23. Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: An add-on and mono-therapy trial. Seizure 2005;14:66-71.
24. Beydoun A. Monotherapy trials with gabapentin for partial epilepsy. Epilepsia 1999;40:S13-S16.
25. Partap S, Fisher PG. Levetiracetam for seizures in children with brain tumors and other cancers. Pediatr Blood Cancer 2009;52: 288-289.
26. Babb TL, Ying Z, Mikuni N, et al. Brain plasticity and cellular mechanisms of epileptogenesis in human and experimental cortical dysplasia. Epilepsia 2000;41:S76-S81.
27. Jacobs KM, Kharazia VN, Prince DA. Mechanisms underlying epileptogenesis in cortical malformations. Epilepsy Res 1999;36: 165-188.
28. Villemure JG, de Tribolet N. Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 1996;9:424-428.
29. Stefan H, Scheler G, Hummel C, et al. Magnetoencephalography (MEG) predicts focal epileptogenicity in cavernomas. J Neurol Neurosurg Psychiatry 2004;75:1309-1313.
30. Aronica E, Yankaya B, Jansen GH, et al. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol 2001;27:223-237.
31. Herman ST. Epilepsy after brain insult: Targeting epileptogenesis. Neurology 2002;59:S21-S26.
32. Cascino GD. Epilepsy and brain tumours. Epilepsia 1990;37:S37-S44.
33. Wolf HK, Roos D, Blumcke I, et al. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol (Berl) 1996;91:376-384.
34. Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: A meta-analysis. Mayo Clin Proc 2004;79:1489-1494.
35. Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien) 1990;103:47-51.
36. Shaw MD. Post-operative epilepsy and the efficacy of anticonvulsant therapy. Acta Neurochir Suppl (Wien) 1990;50:55-57.
37. North JB, Penhall RK, Hanieh A, et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 1983;58:672-677.
38. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001;12:3557-3560.
39. Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce Pglycoprotein in rodent brain: Functional implications for pharmacoresistance. J Neurosci 2002;22:5833-5839.
40. Potschka H, LoscherW. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 2001;12:2387-2389.
41. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: Evidence from microdialysis experiments in rats. Neurosci Lett 2002;327:173-176.
42. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16:197-201.
43. Newman MJ, Dixon R, Toyonaga B. OC144-093, a novel P glycoprotein inhibitor for the enhancement of antiepileptic therapy. Novartis Found Symp 2002;243:213-226.
44. Potschka H, Volk HA, Loscher W. Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. Neuroreport 2004;15:1657-1661.
45. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions. Br J Clin Pharmacol 1995; 40:523-530.
46. Szoeke CE, Newton M, Wood JM, et al. Update on pharmacogenetics in epilepsy: A brief review. Lancet Neurol 2006;5:189-196.
47. BourgV, Lebrun C, Chichmanian RM, et al. Nitrosourea-cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity. Ann Oncol 2001;12:217-219.
48. Oberndorfer S, Piribauer M, Marosi C, et al. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005;72:255-260.
49. French JA, Kanner AM, Bautista J, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Quality Standards Subcommittee of the American Academy of Neurology, American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-1260.
50. Patsalos PN, Fröscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-385.
51. Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: A clinical experience. Seizure 2004;13:142-145.
52. Khurana DS, Kothare SV, Valencia I, et al. Efficacy and tolerability of levetiracetam as adjunctive and monotherapy in pediatric epilepsy. Epilepsia 2004;45:321.
53. Nakken KG, Eriksson AS, Lossius R, et al. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 2003;12:42-46.
54. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-1117.
55. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refactory partial epilepsy: A double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298.
56. Anhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (neurontin) as add-on therapy in patients with partial seizures: A double-blind, placebo-controlled. The International Gabapentin Study Group. Epilepsia 1994;35:795-801.
57. Appelton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: A 12 week, multicentre, double-blind, placebo-controlled study. Gabapentin Pediatric Study Group. Epilepsia 1999;40:1147-1154.
58. Otoul C, Arrigo C, van Rijckevorsel K, et al. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28:72-78.
59. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Neurol 2004;62:1261-1273.
60. Goraya JS, Khurana DS,Valencia I, et al. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol 2008;38:177-180.